To further investigate the performance of A-SAA biomarkers in detecting early-stage HCC, we only included 42 early-stage HCC (BCLC 0-A) patients along with hepatitis and LC patients in this subgroup analysis. This evidence concerns the gene SAA1 and hepatocellular carcinoma.